Network for Excellence in Neuroscience Clinical Trials
The Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, was created to conduct studies of treatments for neurological diseases through partnerships with academia, private foundations, and industry.
Funded by the National Institutes of Health’s National Institute of Neurological Disorders and Stroke (NINDS), NeuroNEXT was designed to:
- Increase efficiency of clinical trials
- Expand the capability of NINDS to test promising new therapies
- Respond quickly as opportunities arise to test promising new treatments for people with neurological disorders
Working with NeuroNEXT is a cooperative venture between NINDS, the Network coordinating centers, and the academic, small business, or industry collaborator. The Network provides a robust, standardized, and accessible infrastructure to facilitate the rapid development and implementation of protocols in neurological disorders, in both adult and pediatric populations. The network includes clinical trial sites, a Clinical Coordinating Center, and a Data Coordinating Center.
NeuroNEXT News
-
2025 Clinical Trials Methodology Course: Call for Applications! Due January 21!
-
NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional) Informational Webinar, Dec. 16th- Registration Open!
-
Register Now! NIH/NINDS Team Science Seminar
-
Heath Care Equity Webinar Series
-
Advancing Research Participation for LGBTQI+ Individuals- NIH Virtual Event
Recent Publications
-
“Moving Things Along: A New Model for the NINDS Clinical Neurotherapeutic Pipeline”
-
NN106: “Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial”
-
NN103 Primary Manuscript: “Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study”
-
Virtual coordinator and site training and reorganization of a multisite consortium upon grant renewal: Challenges of the NeuroNEXT network
-
NN109: “Safety and Efficacy of N-Acetylmannosamine (ManNAc) in Patients with GNE Myopathy: An Open-Label Phase 2 Study”